Currentblue cross blue shield - tennesseePolicy N/A

ANA/ENA Testing

Covers clinical coverage, limitations, and scientific background for antinuclear antibody (ANA), extractable nuclear antigen (ENA) panels, anti-dsDNA, and certain proprietary/multianalyte lupus tests for Blue Cross Blue Shield - Tennessee members.

Policy Summary

Payerblue cross blue shield - tennessee

PolicyANA/ENA Testing

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateN/A

Next Review DateN/A

Key ActionOrder ANA and ENA testing only when clinical suspicion of autoimmune disease is high and document clinical justification; anti-dsDNA testing is limited to up to four times per year after an initial positive ANA.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

≥1:80ANA titer threshold (EULAR/ACR)

≤4/yrAnti-dsDNA covered

19%Repeat ANA conversion

13.4%AVISE 2‑tier positive

Coverage Criteria for ANA, ENA, anti-dsDNA, and Multianalyte Tests

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Covered when ALL of the following are met:

ANA initial testing: Testing for antinuclear antibodies (ANA) meets coverage criteria for individuals in whom the clinical suspicion of autoimmune disease is high based on signs, symptoms, and other factors.

ENA panel testing (for example: nRNP, SS-A, SS-B, Sm, RNP, Scl70, Jo-1) meets coverage when there is abnormal or raised antibody titer or other abnormal immunologic serum findings with clinical correlation to an appropriate autoimmune disorder.

Anti-dsDNA testing meets coverage up to four (4) times per year after an initial positive ANA test when clinically correlated.<=4/year after initial positive ANA

Not medically necessary / exclusions

Not covered / limited scenarios:

Monitoring with ANA: Monitoring of disease activity using ANA testing or ANA titers does NOT meet coverage criteria.

Nonspecific symptoms: ANA and/or ENA testing for individuals with nonspecific symptoms (e.g., fatigue, musculoskeletal pain) in the absence of other findings suggestive of SLE or CTD does NOT meet coverage criteria.

Wellness/general encounter testing: ANA and/or ENA testing during wellness visits or general encounters without abnormal findings does NOT meet coverage criteria.

Specific antibodies without positive ANA: Testing of specific antibodies in the absence of a positive ANA test does NOT meet coverage criteria except in limited exceptions (Anti-Jo-1 for a unique myositis subset; Anti-SSA in the setting of lupus or Sjögren's syndrome).

Proprietary/CB-CAPs: Use of cell‑bound complement activation products (e.g., AVISE Lupus) and other proprietary serum biomarker panels with proprietary algorithms/index scores does NOT meet coverage criteria due to insufficient published evidence for diagnostic or therapeutic benefit.

Proprietary / multianalyte tests

Proprietary multianalyte tests and payer stance:

Proprietary multianalyte panels (examples): Proprietary algorithmic/multianalyte tests exist (for example, ImmunArray 'SLE-key' and Exagen 'AVISE' series) that combine multiple biomarkers and proprietary algorithms/index scores to assist diagnosis, prognosis, or monitoring of SLE.

Coverage stance: These proprietary/multianalyte tests (including AVISE Lupus and similar CB-CAP/MAP assays) are discussed in the evidence section but the policy identifies lack of sufficient published literature for broad coverage; use does NOT meet coverage criteria for diagnosis of SLE in the general application described elsewhere in this policy.

Contexts with demonstrated utility and guideline-concordant ordering

Clinical utility and guideline-informed contexts where testing is informative:

Appropriate ordering of ANA: Order ANA testing only when there is clinical suspicion of SLE or another connective tissue disease; ANA is an entry criterion for SLE classification per EULAR/ACR (positive defined as titer ≥1:80 on HEp-2 cells or equivalent).ANA titer >=1:80

When MAP/CB-CAP testing may be informative: Multianalyte assay panels including cell‑bound complement activation products (MAP/CB-CAP; e.g., AVISE) may aid diagnosis or prediction of progression in selected patients (for example, ANA‑positive or clinically suspected patients); some studies report MAP scores >0.8 predicting transition to classifiable SLE and higher subsequent rates of SLE diagnosis in MAP/AVISE‑positive cohorts.MAP score >0.8

Repeat testing guidance: Do not routinely repeat ANA testing after an initial negative result within two years in the absence of new clinical indications; repeat testing has low yield.repeat within 2 years not recommended absent new findings

Use of ANA subserologies: Do not order ANA subserologies or broad autoantibody panels without a positive ANA and clinical suspicion, consistent with ACR/Choosing Wisely recommendations.positive ANA required

SLE classification and testing criteria

Classification and diagnostic criteria relevant to SLE-related testing:

EULAR/ACR entry criterion: A positive ANA at a titer of ≥1:80 on HEp-2 cells (or an equivalent positive test) is required as the entry criterion before applying the additive EULAR/ACR criteria for SLE; if absent, the condition is not classified as SLE per EULAR/ACR.>=1:80

SLICC overall classification: Per the 2012 SLICC criteria, an individual is classified as having SLE if they meet at least 4 cumulative criteria including at least one clinical criterion and one immunologic criterion; criteria may be accumulated over time and need not be concurrent.>=4 criteria with >=1 clinical and >=1 immunologic

SLICC clinical criteria examples: Examples of clinical criteria include acute or chronic cutaneous lupus, nonscarring alopecia, oral/nasal ulcers, joint disease, serositis, renal involvement (urine protein-to-creatinine representing 500 mg protein/24 hours or red blood cell casts), neurologic manifestations, hemolytic anemia, leukopenia/lymphopenia, and thrombocytopenia.

SLICC immunologic criteria examples: Immunologic criteria include ANA, anti-dsDNA, anti-Sm, antiphospholipid antibodies, low complement (C3/C4/CH50), and a direct Coombs test in the absence of hemolytic anemia.

The policy does not support routine use of cell-bound complement activation products (CB-CAPs) or proprietary multianalyte serum biomarker panels that report proprietary algorithm/index scores (for example, AVISE Lupus or Avise CTD) for diagnosis of systemic lupus erythematosus or connective tissue diseases. These tests do not meet coverage criteria in this document due to insufficient published evidence demonstrating required clinical benefit. Laboratories offering such assays should provide validation and clinical utility data if seeking coverage consideration.

ANA testing should not be used as a general screening test in asymptomatic individuals. Per Choosing Wisely and ACR guidance, do not order ANA as a screening test in patients without specific signs or symptoms of SLE or another connective tissue disease; ANA testing is appropriate only when there is clinical suspicion based on history and examination and documentation should reflect that suspicion.

For sclerosing skin diseases (for example localized scleroderma or systemic sclerosis), guidelines recommend against routine ANA screening. Testing for extractable nuclear antigens (ENA) should be reserved to confirm or exclude systemic sclerosis when clinically indicated rather than as a routine screen.

The provided document excerpts do not list additional explicit exclusion criteria beyond those noted for proprietary multianalyte tests and routine or screening use of ANA/ENA; no other specific absolute exclusions are described in the cited chunks.

Ordering specific autoantibody tests when the ANA is negative is generally not supported by coverage except in limited, defined circumstances. The policy allows exceptions for Anti-Jo-1 in a unique clinical subset of myositis and for Anti-SSA (Ro) when testing is clinically indicated in the setting of lupus or Sjögren’s syndrome; otherwise, testing specific antibodies with a negative ANA does not meet coverage criteria.

Routine repeat ANA testing after an initial negative result has low clinical utility and is discouraged. A retrospective study showed only 19% of patients converted to ANA-positive within two years after an initial negative repeat and this rarely changed diagnosis; therefore routine repeat testing and ordering of broad ANA subserologies without a positive ANA and supporting clinical findings is not indicated.

In pediatric patients, ANA and other autoantibody testing should not be ordered unless there is a strong clinical suspicion or specific signs of autoimmune disease. The American Academy of Pediatrics specifically advises against routine ANA testing in children without clear clinical indications.

Within the provided document excerpts there are no additional explicit statements labeled as 'not medically necessary' beyond the policy language already addressing testing of specific antibodies with negative ANA, repeat testing after a negative ANA, pediatric testing without suspicion, and the proprietary multianalyte/CB-CAP tests noted elsewhere.

Testing Thresholds and Coding-Adjacent Criteria

inv-14: ANA titer entry threshold — >=1:80 on HEp-2 cells

ANA titer threshold (entry)>=1:80 on HEp-2 cells

ContextRequired entry criterion per EULAR/ACR classification for SLE

ImplicationIf absent, SLE classification per EULAR/ACR is not applied

inv-15: ANA titer threshold — >= 1:80 on HEp-2 cells or equivalent

ANA titer threshold>= 1:80 on HEp-2 cells or equivalent

Source guidanceStated as the EULAR/ACR entry criterion for SLE classification

Clinical usePositive ANA at this level permits application of additive classification criteria

inv-16: Urine protein criteria for renal SLICC — protein-to-creatinine ratio representing 500 mg protein/24 hours or red blood cell casts

Urine protein criterionUrine protein-to-creatinine ratio representing 500 mg protein/24 hours

Alternate renal findingPresence of red blood cell casts meets renal SLICC clinical criterion

UseCounts as a clinical criterion toward SLICC classification for SLE

Provider Actions, Documentation, and Authorization Guidance

Prior Authorization

Prior authorization considerations for MAP/AVISE

Prior authorization considerations for multianalyte panels (MAP/AVISE): Payers may require prior authorization or clinical justification when MAPs or CB-CAPs (e.g., AVISE Lupus) are requested because these assays include proprietary algorithms and multianalyte indices. Clinical utility and analytic validation data (published studies showing reproducibility, predictive value, and impact on management) may be requested to support coverage. Evidence cited in the literature (eg, Dervieux et al., Ramsey‑Goldman et al., Wallace et al.) describing assay performance, reproducibility, and clinical impact should be available to support medical necessity.

MAP/CB‑CAP tests (eg, AVISE Lupus) may prompt payer review for clinical utility and analytic validation data
Provide published validation and clinical utility studies when requesting coverage or prior authorization

Documentation Required

LDT validation and coverage review

LDTs are regulated under CLIA as high‑complexity laboratory‑developed tests and are not FDA‑cleared/approved. Payers may require documentation of laboratory validation, method description, and evidence of analytic performance when coverage is sought for LDTs.

Laboratory‑developed tests (LDTs) are CLIA‑regulated; FDA clearance/approval is not required for clinical use
Payers may request validation data (eg, precision, stability, reproducibility) and method details for in‑house assays

Denial Risk

Situations triggering denial

Situations likely to trigger denial: testing without objective abnormal findings or strong clinical suspicion; screening during wellness visits or general encounters without abnormal results; testing ANA/ENA for nonspecific symptoms (eg, isolated fatigue or musculoskeletal pain) without other suggestive signs of autoimmune disease; ordering subserologies in the absence of a positive ANA and clinical suspicion.

ANA/ENA testing during wellness or general encounters without abnormal findings — denial risk
ANA/ENA testing for nonspecific symptoms alone (eg, fatigue, isolated musculoskeletal pain) — denial risk
Ordering ANA subserologies without a positive ANA and clinical suspicion — denial risk

Denial Risk

Unnecessary subserology testing risk

Unnecessary subserology testing risk: Do not order ANA subserologies (ENA panel or other specific autoantibody tests) unless there is a positive ANA and clinical suspicion of immune‑mediated disease. Excessive or reflexive subserology ordering without appropriate entry criteria increases likelihood of denial and inappropriate resource use.

Do not order ANA subserologies without a positive ANA and appropriate clinical signs/symptoms
Autoantibody panels ordered without evidence of rheumatic disease in children are discouraged

Denial Risk

Inappropriate routine ordering risk

Inappropriate routine ordering risk: Routine or screening ANA and autoantibody testing in low‑pretest‑probability populations (including children without strong suspicion) is discouraged and may be denied. Repeat ANA testing after a confirmed negative result has low utility and frequently does not change diagnosis or management.

Avoid routine ANA/autoantibody testing in patients without strong clinical suspicion (especially pediatric patients)
Repeat ANA testing after a negative result generally has low utility and may be denied

Documentation Required

Required clinical documentation

Required clinical documentation: Provide documentation demonstrating high clinical suspicion and objective findings consistent with autoimmune disease. Documentation should include relevant signs/symptoms that meet entry criteria (eg, for SLE: ANA ≥1:80 on HEp‑2 or equivalent, mucocutaneous findings, serositis, renal or neurologic findings), prior test results (including ANA titer and method), and how the test result will impact management.

Document signs/symptoms that meet diagnostic entry criteria (eg, ANA ≥1:80 on HEp‑2 or equivalent when applicable)
Include prior ANA/ENA/dsDNA results, specimen/test details, and intended clinical impact of results
For MAP/CB‑CAP or LDT testing, include analytic validation references and rationale for use

Note

Reflex testing guidance

Reflex testing guidance: Reflex ENA and anti‑dsDNA testing is appropriate for specific ANA patterns and titers (eg, nuclear homogeneous, speckled, Scl‑70-like, nucleolar, centromeric, cytoplasmic patterns) at defined titres (commonly >1:160) where identification of specific autoantibodies is clinically informative. Laboratories and ordering clinicians should follow staged algorithms to limit unnecessary downstream testing.

Reflex ENA and anti‑dsDNA for specific ANA patterns (eg, homogeneous, speckled, Scl70‑like) at titres >1:160
Execute targeted reflex tests rather than broad subserology panels when pattern/titer indicates specific antibodies

Step Therapy

Step/sequence guidance for repeat testing

Step/sequence guidance for repeat testing and step therapy note: Routine repeat ANA testing after an initial negative result is not recommended due to low utility and high cost. No formal step‑therapy sequencing is specified in this policy; there are no required prior step‑therapy trials described for ANA/ENA/dsDNA testing beyond adherence to documented clinical criteria and, where applicable, any payer prior authorization process.

Do not routinely repeat ANA after a confirmed negative result; repeat testing showed low yield within two years
No step‑therapy sequencing is specified — adherence to documentation and prior authorization (if required) is the operational requirement

Background and Clinical Rationale

Antinuclear antibody (ANA) assays detect autoantibodies directed against intracellular antigens and are used as a screening tool for systemic autoimmune rheumatic diseases (SARDs) such as systemic lupus erythematosus, Sjögren’s syndrome, mixed connective tissue disease, systemic sclerosis, and inflammatory myopathies. Indirect immunofluorescence on HEp-2 cell substrate is the reference method because it provides pattern and titer information; solid-phase assays offer automation but test a narrower set of antigens, which can affect sensitivity and specificity depending on cutoffs and methods.

Definitions and Terminology

inv-34: ENA — Extractable nuclear antigens (Sm, U1 RNP, Ro, La) and their role

DefinitionExtractable nuclear antigens (ENA) are autoantigens historically extracted into saline and tested to assist in autoimmune disease diagnosis

Common ENA targetsIncludes Sm, U1 RNP, Ro, and La antigens

Clinical roleENA testing aids identification of specific autoantibodies to support diagnosis and classification of systemic autoimmune rheumatic diseases

inv-35: IIF / HEp-2 — Indirect immunofluorescence on HEp-2 cells as reference method for ANA

MethodIndirect immunofluorescence (IIF) on HEp-2 cell substrate

RationaleHEp-2 cells contain most clinically important autoantigens and provide staining pattern and titer information

StatusIIF/HEp-2 remains the reference method of choice for ANA detection (ACR)

inv-36: CB-CAPs / MAP / AVISE — Cell-bound complement activation products and multianalyte panels description

DefinitionCell-bound complement activation products (CB-CAPs) are measures of C4d bound to erythrocytes (EC4d) and B cells (BC4d) used with autoantibody assays in multianalyte panels (MAP/AVISE)

Assay formatMeasured by quantitative flow cytometry and reported within a multianalyte two-tiered index score

Clinical claimUsed by proprietary assays (e.g., Exagen AVISE) to assist diagnosis and predict progression of SLE in selected studies

inv-37: ANA entry criterion (EULAR/ACR) — ANA at a titer >=1:80 on HEp-2 cells or equivalent

ANA entry criterion>=1:80 on HEp-2 cells or equivalent

PurposeRequired as entry criterion before applying EULAR/ACR additive criteria for SLE

ConsequenceAbsence of ANA at this threshold implies SLE classification per EULAR/ACR should not be applied

inv-38: ANA entry criterion (EULAR/ACR) duplicate — Antinuclear antibodies at a titer of >=1:80 used as entry criterion

Entry titer restatedAntinuclear antibodies at a titer of >=1:80 on HEp-2 cells or equivalent positive test

Guideline sourceEULAR/ACR joint guideline for SLE classification (Aringer et al., 2019)

Clinical implicationPermits use of additive clinical and immunologic criteria for SLE if met

inv-39: SLICC classification — 2012 SLICC classification criteria summary

SLICC summary2012 SLICC criteria require >=4 cumulative criteria including at least one clinical and one immunologic criterion to classify SLE

Clinical examplesClinical criteria include cutaneous, renal, neurologic, hematologic, serositis, and joint manifestations

Immunologic examplesImmunologic criteria include ANA, anti-dsDNA, anti-Sm, antiphospholipid antibodies, low complement, direct Coombs without hemolytic anemia

inv-40: Multianalyte assay panel with complement activation products — Definition

DefinitionMultianalyte assay panel with complement activation products measures multiple biomarkers including CB-CAPs to assist diagnosis of SLE

ReportingOften reported as a composite or two-tiered index score (positive/negative) used in proprietary tests

Evidence baseRandomized prospective trials and analytical validation studies (e.g., Wallace 2019; Dervieux et al. 2017) have been published

inv-41: Antinuclear antibody (ANA) testing — Definition and role

DefinitionAntinuclear antibody (ANA) testing detects autoantibodies targeting intracellular antigens and is used to evaluate systemic rheumatic diseases

MethodsReference method is IIF on HEp-2 cells, which provides pattern and titer; automated solid-phase assays offer higher throughput but narrower antigen coverage

Clinical roleUsed as an initial screening test in patients with clinical suspicion of autoimmune disease, not for routine population screening

Policy Summary

Payerblue cross blue shield - tennessee

PolicyANA/ENA Testing

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateN/A

Next Review DateN/A

SourceLink

On This Page